Skip to main content
SpringerLink
Log in

Pharmakotherapie der chronischen Herzinsuffizienz

So lässt sich das Herz stärken

Pharmacotherapy in chronic Heart Failure

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Das Spektrum der Therapieoptionen der chronischen Herzinsuffizienz ist in den vergangenen Jahren deutlich breiter geworden. Hierzu tragen neben neuen Behandlungsmöglichkeiten zugrundeliegender kardiovaskulärer Komorbiditäten wie koronarer Herzerkrankung oder Herzklappendysfunktionen auch Fortschritte in der medikamentösen Therapie bei.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Ponikowski P, Voors AA, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–200

    Article  PubMed  Google Scholar 

  2. Deutsche Herzstiftung. 27. Deutscher Herzbericht. 2015.

  3. American Heart Association. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation. 1999;90:644–5

    Google Scholar 

  4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35

    Article  Google Scholar 

  5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91

    Article  Google Scholar 

  6. Gard R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450–6

    Article  Google Scholar 

  7. Granger C, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6

    Article  CAS  PubMed  Google Scholar 

  8. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75

    Article  CAS  PubMed  Google Scholar 

  9. Gheorghiade M, Böhm M, Greene SJ et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2010;309:1125–35

    Article  Google Scholar 

  10. McMurray JJ, Krum H, Abraham WT et al. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016;374;16:1521–32

    Article  CAS  PubMed  Google Scholar 

  11. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21

    Article  CAS  PubMed  Google Scholar 

  12. Pitt B, Zannad F, Remme WJ et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med. 1999;341:709–17

    Article  CAS  PubMed  Google Scholar 

  13. Hjalmarson A, Goldstein B, Fagerberg H et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA. 2000;283:1295–302

    Article  CAS  PubMed  Google Scholar 

  14. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival study (COPERNICUS). Circulation. 2002;160:2194–9

    Article  Google Scholar 

  15. Willenheimer R, van Veldhuisen DJ, Silke B et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;16:2426–35

    Article  Google Scholar 

  16. Kotecha D, Holmes J, Krum H et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384;9961:2235–43

    Article  CAS  PubMed  Google Scholar 

  17. McMurray J, Packer M, Desai A et al. Angiotensin—Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371:993–1004

    Article  PubMed  Google Scholar 

  18. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11–22

    Article  PubMed  Google Scholar 

  19. Withering, W. An Account of the Foxglove and Some of its Medical Uses: With Practical Remarks on Dropsy and other Diseases. Printed by Swinney, Birmingham, 1785

  20. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33

    Article  Google Scholar 

  21. Ouyang AJ, Krum H, Abraham WT et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol. 2015;115:901–6

    Article  CAS  PubMed  Google Scholar 

  22. Ahmed A, Rich MW, Love TE et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–86

    Article  CAS  PubMed  Google Scholar 

  23. Pitt B, Pfeffer MA, Assmann SF et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–92

    Article  CAS  PubMed  Google Scholar 

  24. Pfeffer MA, Claggett B, Assmann SF et al. Regional ariation in patients and outcomes in the Treatment Of Preserved Cardiac function heart failure with an Aldosterone antagonist Trial (TOPCAT). Circulation. 2014;134: epub

  25. Edelmann F, Wachter R, Schmidt AG et al. Effect of Spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. JAMA. 2013;309:781–91

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Ernst-Grube-Str. 40, D-06120, Halle, Deutschland

    Alexander Vogt

  2. Universitätsklinikum Würzburg, Würzburg, Deutschland

    Stefan Frantz

Authors
  1. Alexander Vogt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Frantz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander Vogt.

Additional information

INTERESSENKONFLIKT

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: Dr. Vogt: keine; Prof. Frantz: Firmenunterstützung bei Studien für Janssen Cilag, Mapi Life Sciences, Medtronic, Novartis; Firmenunterstützung bei Veranstaltungen für Bayer, Boehringer, BMS, Astra. Vortragstätigkeit für Amgen, AstraZeneca, Bayer Vital, Boehringer, BMS, Daiichi Sankyo, MSD, Novarrtis, Pfizer, Sanofi, Servier, Vifor; Honorare Advisory Boards durch die Firmen Bayer, Boehringer, MSD, Pfizer.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vogt, A., Frantz, S. So lässt sich das Herz stärken. MMW - Fortschritte der Medizin 159, 42–48 (2017). https://doi.org/10.1007/s15006-017-9590-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9590-9

Keywords

Search

Navigation